Trial Profile
Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever Vaccines Followed by a Booster of the Malaria Vaccine.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK 257049 (Primary) ; Measles and rubella virus vaccine; Retinol; Yellow fever vaccine
- Indications Malaria
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; GSK
- 27 Oct 2020 Status changed from active, no longer recruiting to completed.
- 14 Apr 2020 Planned End Date changed from 18 Dec 2020 to 7 Oct 2020.
- 16 Mar 2020 Primary(Anti-Circumsporozoite (Anti-CS) Antibody Concentrations, One Month Post Dose 3 of SB257049) endpoint has been met as per Results published in the Vaccine.